ENDO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENDO, and what generic alternatives to ENDO drugs are available?
ENDO has one hundred and thirty-six approved drugs.
There are forty-three US patents protecting ENDO drugs. There is one tentative approval on ENDO drugs.
There are two hundred and seventy-seven patent family members on ENDO drugs in forty-two countries and two hundred and seventy-three supplementary protection certificates in seventeen countries.
Summary for ENDO
| International Patents: | 277 |
| US Patents: | 43 |
| Tradenames: | 111 |
| Ingredients: | 105 |
| NDAs: | 136 |
| Patent Litigation for ENDO: | See patent lawsuits for ENDO |
| PTAB Cases with ENDO as petitioner: | See PTAB cases with ENDO as petitioner |
| PTAB Cases with ENDO as patent owner: | See PTAB cases with ENDO as patent owner |
Drugs and US Patents for ENDO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | ISOSORBIDE DINITRATE | isosorbide dinitrate | TABLET;ORAL | 211290-001 | Nov 23, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-006 | Apr 12, 2023 | DISCN | Yes | No | 10,010,575 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | THEO-24 | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 087943-002 | Aug 22, 1983 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENDO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-007 | Dec 9, 2011 | 8,309,060 | ⤷ Sign Up |
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-007 | Dec 9, 2011 | 8,309,122 | ⤷ Sign Up |
| Endo Operations | TESTIM | testosterone | GEL;TRANSDERMAL | 021454-001 | Oct 31, 2002 | 7,608,610 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 1% | ➤ Subscribe | 2008-08-21 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | Injection | 1 mg/mL ampules | ➤ Subscribe | 2016-03-09 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2011-03-09 |
| ➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-05-29 |
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
| ➤ Subscribe | Gel | 10 mg/actuation | ➤ Subscribe | 2012-08-14 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Injection | 250 mg/mL | ➤ Subscribe | 2014-06-11 |
| ➤ Subscribe | Injection | 20 units/mL, 1 mL | ➤ Subscribe | 2018-03-23 |
| ➤ Subscribe | Extended-release Tablets | 5 mg, 10 mg, 20 mg and 40 mg | ➤ Subscribe | 2007-11-23 |
| ➤ Subscribe | Extended-release Tablets | 30 mg | ➤ Subscribe | 2008-06-12 |
International Patents for ENDO Drugs
Supplementary Protection Certificates for ENDO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2782584 | 132021000000197 | Italy | ⤷ Sign Up | PRODUCT NAME: ESTRADIOLO (17SS-ESTRADIOLO) IN PARTICOLARE NELLA FORMA EMIIDRATA, E PROGESTERONE COMPRENDENTI LE VARIE FORME DI ESTRADIOLO (17SS-ESTRADIOLO), QUALI LE FORME IDRATE E SOLVATATE, INCLUDENDO LA FORMA EMIIDRATA, ED I SUOI SALI.(BIJUVA); AUTHORISATION NUMBER(S) AND DATE(S): BE582231, 20210406;048335018 -048335020, 20210517 |
| 2269603 | PA2015041 | Lithuania | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUSUM; REGISTRATION NO/DATE: EU/1/09/538/001, EU/1/09/538/003, EU/1/09/538/004, EU/1/09/538/006-010 20120723 |
| 0392059 | SPC/GB02/046 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
